There is insufficient evidence to draw conclusions regarding the benefits of first-generation antipsychotics (FGAs) vs. second-generation antipsychotics (SGAs) for adults with schizophrenia.
Mylan announced the launch of Olanzapine Orally Disintegrating Tablets (ODT), the generic version of Eli Lilly's Zyprexa Zydis.
Agitation is a "common and important clinical management problem" in both major psychotic and mood disorders.
Zyprexa Relprevv (extended-release olanzapine injectable suspension, from Lilly) has been FDA approved for the treatment of schizophrenia in adults.
Youth prescribed antipsychotic medication should be monitored for exaggerated weight gain, and agents other than olanzapine, clozapine, and risperidone may be best in patients where obesity is a pre-existing concern, according to a review published in Obesity Reviews.
The FDA stated the study results were inconclusive regarding the investigation of two deaths following the injection of Zyprexa Relprevv (olanzapine pamoate; Eli Lilly) from June 2013.
Atypical antipsychotic drugs induce insulin resistance even in the absence of weight gain and mechanisms regulating eating behavior.
This case report describes the first documented case of reversible, fluoxetine-induced hyperthyroidism in a patient after 10 weeks of treatment.
A new article reports on a study comparing the safety and efficacy of olanzapine/fluoxetine combination therapy (OFC) v.s fluoxetine monotherapy in patients with treatment-resistant major depressive disorder (MDD).
There is limited evidence for the comparative benefits and harms of antipsychotics in children and young adults.